Cognition Therapeutics is a clinical-stage biopharmaceutical company developing a single drug, zervimesine, for neurodegenerative diseases. Zervimesine is an oral, once-daily small molecule that works by blocking toxic protein oligomers (including amyloid beta and α-synuclein) from binding to neuronal synapses, protecting neurons from damage. The primary target indications are Alzheimer's disease and dementia with Lewy bodies. Cognition has no approved products and no product revenue. Operations are funded primarily through grants from the National Institute on Aging, which has provided approximately $171M cumulatively. In AD, Cognition completed the Phase 2 SHINE study, which showed participants on zervimesine experienced 38% less cognitive decline versus placebo; a biomarker subgroup showed a 95% reduction in decline, a finding that shapes Cognition's Phase 3 enrichment strategy. The ongoing Phase 2 START study (545 patients) completed enrollment in December 2025, with topline results expected after all patients complete 18 months of treatment. In DLB, the completed Phase 2 SHIMMER study showed broad benefits across neuropsychiatric, functional, cognitive, and motor outcomes. Cognition's Phase 3 priority in DLB is psychosis — hallucinations and delusions affecting up to 80% of DLB patients, with no currently approved treatments. Cognition retains worldwide rights to zervimesine and is actively pursuing partnership discussions for Phase 3 funding and potential commercialization, as NIA grants are less likely to fund later-stage trials.